DGX Stock Overview
Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally.
Quest Diagnostics Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$141.03|
|52 Week High||US$174.16|
|52 Week Low||US$125.77|
|1 Month Change||-0.43%|
|3 Month Change||7.35%|
|1 Year Change||7.39%|
|3 Year Change||43.85%|
|5 Year Change||30.61%|
|Change since IPO||3,929.43%|
Recent News & Updates
Investors Should Be Encouraged By Quest Diagnostics' (NYSE:DGX) Returns On Capital
What are the early trends we should look for to identify a stock that could multiply in value over the long term? One...
At US$136, Is It Time To Put Quest Diagnostics Incorporated (NYSE:DGX) On Your Watch List?
Today we're going to take a look at the well-established Quest Diagnostics Incorporated ( NYSE:DGX ). The company's...
|DGX||US Healthcare||US Market|
Return vs Industry: DGX exceeded the US Healthcare industry which returned 2.5% over the past year.
Return vs Market: DGX exceeded the US Market which returned -12.9% over the past year.
|DGX Average Weekly Movement||3.4%|
|Healthcare Industry Average Movement||10.6%|
|Market Average Movement||7.8%|
|10% most volatile stocks in US Market||16.8%|
|10% least volatile stocks in US Market||2.9%|
Stable Share Price: DGX is less volatile than 75% of US stocks over the past 3 months, typically moving +/- 3% a week.
Volatility Over Time: DGX's weekly volatility (3%) has been stable over the past year.
About the Company
Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to patients, clinicians, hospitals, independent delivery networks, health plans, employers, direct contract entities, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile paramedics, nurses, and other health and wellness professionals.
Quest Diagnostics Fundamentals Summary
|DGX fundamental statistics|
Is DGX overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|DGX income statement (TTM)|
|Cost of Revenue||US$6.57b|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||15.97|
|Net Profit Margin||17.55%|
How did DGX perform over the long term?See historical performance and comparison
1.9%Current Dividend Yield
Does DGX pay a reliable dividends?See DGX dividend history and benchmarks
|Quest Diagnostics dividend dates|
|Ex Dividend Date||Jul 05 2022|
|Dividend Pay Date||Jul 20 2022|
|Days until Ex dividend||44 days|
|Days until Dividend pay date||59 days|
Does DGX pay a reliable dividends?See DGX dividend history and benchmarks
Is Quest Diagnostics undervalued compared to its fair value and its price relative to the market?
Valuation Score 4/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PB vs Industry
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: DGX ($141.03) is trading below our estimate of fair value ($321.94)
Significantly Below Fair Value: DGX is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: DGX is good value based on its PE Ratio (8.8x) compared to the US Healthcare industry average (19x).
PE vs Market: DGX is good value based on its PE Ratio (8.8x) compared to the US market (15.3x).
Price to Earnings Growth Ratio
PEG Ratio: DGX's earnings are forecast to decline next year, so we can't calculate its PEG ratio.
Price to Book Ratio
PB vs Industry: DGX's PB Ratio (2.6x) is in line with the US Healthcare industry average.
How is Quest Diagnostics forecast to perform in the next 1 to 3 years based on estimates from 14 analysts?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: DGX's earnings are forecast to decline over the next 3 years (-0.5% per year).
Earnings vs Market: DGX's earnings are forecast to decline over the next 3 years (-0.5% per year).
High Growth Earnings: DGX's earnings are forecast to decline over the next 3 years.
Revenue vs Market: DGX's revenue (0.5% per year) is forecast to grow slower than the US market (7.8% per year).
High Growth Revenue: DGX's revenue (0.5% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: DGX's Return on Equity is forecast to be low in 3 years time (14.7%).
How has Quest Diagnostics performed over the past 5 years?
Past Performance Score4/6
Past Performance Score 4/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: DGX has high quality earnings.
Growing Profit Margin: DGX's current net profit margins (17.5%) are higher than last year (17.4%).
Past Earnings Growth Analysis
Earnings Trend: DGX's earnings have grown significantly by 26.4% per year over the past 5 years.
Accelerating Growth: DGX's earnings growth over the past year (4.5%) is below its 5-year average (26.4% per year).
Earnings vs Industry: DGX earnings growth over the past year (4.5%) underperformed the Healthcare industry 8.8%.
Return on Equity
High ROE: DGX's Return on Equity (30.2%) is considered high.
How is Quest Diagnostics's financial position?
Financial Health Score4/6
Financial Health Score 4/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: DGX's short term assets ($2.5B) exceed its short term liabilities ($1.7B).
Long Term Liabilities: DGX's short term assets ($2.5B) do not cover its long term liabilities ($5.2B).
Debt to Equity History and Analysis
Debt Level: DGX's net debt to equity ratio (50.4%) is considered high.
Reducing Debt: DGX's debt to equity ratio has reduced from 80.3% to 61.4% over the past 5 years.
Debt Coverage: DGX's debt is well covered by operating cash flow (49.7%).
Interest Coverage: DGX's interest payments on its debt are well covered by EBIT (15.3x coverage).
What is Quest Diagnostics's current dividend yield, its reliability and sustainability?
Dividend Score 5/6
Future Dividend Coverage
Current Dividend Yield
Upcoming Dividend Payment
Dividend Yield vs Market
Notable Dividend: DGX's dividend (1.87%) is higher than the bottom 25% of dividend payers in the US market (1.58%).
High Dividend: DGX's dividend (1.87%) is low compared to the top 25% of dividend payers in the US market (4.11%).
Stability and Growth of Payments
Stable Dividend: DGX's dividends per share have been stable in the past 10 years.
Growing Dividend: DGX's dividend payments have increased over the past 10 years.
Earnings Payout to Shareholders
Earnings Coverage: With its low payout ratio (16.3%), DGX's dividend payments are well covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: With its low cash payout ratio (19.3%), DGX's dividend payments are well covered by cash flows.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Steve Rusckowski (64 yo)
Mr. Stephen H. Rusckowski, also known as Steve, has been the Chief Executive Officer, President and Director of Quest Diagnostics Incorporated since May 1, 2012 and has been its Chairman since January 1, 2...
CEO Compensation Analysis
Compensation vs Market: Steve's total compensation ($USD14.56M) is about average for companies of similar size in the US market ($USD13.34M).
Compensation vs Earnings: Steve's compensation has been consistent with company performance over the past year.
Experienced Management: DGX's management team is seasoned and experienced (9 years average tenure).
Experienced Board: DGX's board of directors are considered experienced (8.1 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: DGX insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Quest Diagnostics Incorporated's employee growth, exchange listings and data sources
- Name: Quest Diagnostics Incorporated
- Ticker: DGX
- Exchange: NYSE
- Founded: 1967
- Industry: Health Care Services
- Sector: Healthcare
- Implied Market Cap: US$16.552b
- Shares outstanding: 117.37m
- Website: https://www.questdiagnostics.com
Number of Employees
- Quest Diagnostics Incorporated
- 500 Plaza Drive
- New Jersey
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/05/21 00:00|
|End of Day Share Price||2022/05/20 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.